Last updated: 18 พ.ย. 2562 |
PUBLISHED : 18 Nov 2019 - 13:18
The barriers facing patients accessing medicinal cannabis will be placed under scrutiny during a Parliamentary inquiry into how Australia regulates the drug. Barriers confronting patients trying to access medicinal cannabis in Australia will be scrutinised in a Parliamentary inquiry into how the drug is regulated.
The Greens said the medicinal cannabis system is “broken” and in urgent need of reform as their push for an inquiry into access to the drug won support in the Senate on Thursday.
But the Federal government has rejected the need for review saying it continues to enable access to medicinal cannabis for those in need while maintaining safeguards of its use.
Health Minister Greg Hunt is seen inspecting the cannabis plants.
Source : AAP
Greens leader Richard Di Natale said patients are being denied access to medicinal cannabis by a “dysfunctional” system that is not working for them.
“The failure of the current system has led to thousands of patients being denied access to medicine, with many being forced to turn to the black market,” he said.
“Doctors shouldn’t be turning away sick people because of the complexities of prescribing cannabis.”
Greens leader Richard Di Natale.
Source : AAP
The use of medicinal cannabis became legal in Australia at a federal level in 2016.
Research has shown the drug can help manage some conditions including chronic pain, multiple sclerosis, epilepsy and chemotherapy-induced nausea and vomiting.
Liberal Senator Jonathon Duniam said calls for the inquiry ignored the “significant progress” made to date in increasing doctors and patients access to the drug.
“The Morrison government continues to make it easier for doctors to access medicinal cannabis products more rapidly while maintaining strict safeguards for individual and community safeguards,” he told the Senate.
The Senate's community affairs committee will look at the suitability of the drug for government subsidies through the Pharmaceutical Benefits Schemes.
It will also review "delays in access” due to the importation of medicinal cannabis and a “shortage” of the drug's products being manufactured in Australia.
Cannabis plants are seen growing at Medifarm on the Sunshine Coast.
Source : AAP
This would include reviewing the impacts on the mental and physical well-being of those patients “struggling to access” medicinal cannabis.
Other points of reference include barriers for those in rural and remote areas and “significant” financial barriers in accessing the medicinal drug legally.
“It’s been shoehorned into a system that is not fit for purpose, and all that’s achieved is delays, expense and suffering for Australian patients,” Mr Di Natale said.
The Greens Leader said the inquiry would uncover “deep failures” of accessing the medicinal cannabis system through the Therapeutic Goods Administration.
“For far too long patients have been denied access to essential medication by a system that simply doesn’t work as intended,” she said.
“This inquiry will… look into whether doctors have the information they need to prescribe it, and whether patients have access to the medicine they need.”
Senator Duniam said over 23,000 applications for medicinal cannabis had been approved to nearly 15,000 patients via a special access scheme via the TGA, since January 2016.
“There is no barrier to applications to the PBS. PBS applicants must, by law, be determined on medicinal, not political grounds as proposed in this motion,” he told the Senate.
The Greens won support for the inquiry 35 votes to 31, with Labor and crossbench senators helping the minor party defeat the Federal government.
The inquiry will also compare Australia's regime to other countries and investigate the training and education of doctors in relation to the treatment.
Mr Di Natale said it would help endless layers of “confusing red tape” impeding access to medicinal cannabis.
“Patients deserve to finally have hope that they’ll be able to access the medicine they desperately need,” he said.
The Australian Greens will chair the inquiry, which is due to receive submissions shortly.
The committee is due to report on 12 February, 2020.
With additional reporting from AAP